Ondine Biomedical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA68234M2058
GBP
0.14
0.05 (61.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Diaceutics Plc
Oxford Biomedica Plc
Optibiotix Health Plc
Scancell Holdings Plc
Oxford BioDynamics Plc
Ondine Biomedical, Inc.
PureTech Health Plc
4basebio Plc
e-Therapeutics Plc
HemoGenyx Pharmaceuticals Plc
Oncimmune Holdings Plc

Why is Ondine Biomedical, Inc. ?

1
Negative results in Dec 25
  • OPERATING CASH FLOW(Y) Lowest at GBP -21.54 MM
  • OPERATING PROFIT(Q) Lowest at GBP -9.25 MM
  • PRE-TAX PROFIT(Q) Lowest at GBP -9.16 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 6.62%, its profits have risen by 361%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 6.62% in the last 1 year, much lower than market (FTSE 100) returns of 17.87%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ondine Biomedical, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Ondine Biomedical, Inc.
-100.0%
2.36
42.38%
FTSE 100
17.87%
1.52
11.77%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-8.47%
EBIT Growth (5y)
24.65%
EBIT to Interest (avg)
-20.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.42
Sales to Capital Employed (avg)
20.27
Tax Ratio
39.42%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
345.04%
ROE (avg)
123.78%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
39.76
EV to EBIT
22.53
EV to EBITDA
14.43
EV to Capital Employed
-18.96
EV to Sales
1.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
175.31%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at GBP -9.16 MM

RAW MATERIAL COST(Y)

Fallen by -97.05% (YoY

-13What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at GBP -21.54 MM

OPERATING PROFIT(Q)

Lowest at GBP -9.25 MM

PRE-TAX PROFIT(Q)

Lowest at GBP -9.16 MM

NET PROFIT(Q)

Lowest at GBP -9.16 MM

Here's what is working for Ondine Biomedical, Inc.

Raw Material Cost
Fallen by -97.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ondine Biomedical, Inc.

Operating Cash Flow
Lowest at GBP -21.54 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (GBP MM)

Operating Profit
Lowest at GBP -9.25 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite negative

Operating Profit (GBP MM)

Pre-Tax Profit
Lowest at GBP -9.16 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (GBP MM)

Pre-Tax Profit
At GBP -9.16 MM has Fallen at -41.43%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (GBP MM)

Net Profit
Lowest at GBP -9.16 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (GBP MM)

Net Profit
At GBP -9.16 MM has Fallen at -41.43%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (GBP MM)